Abstract:Objective: To assess the performance of continuous glucose monitoring (CGM) metrics in predicting development of gestational diabetes mellitus (GDM) and adverse pregnancy outcomes. Methods: In a prospective observational study, CGM data were collected from 760 pregnant participants. Predictive CGM-based models were built using logistic and elastic net regression. Predictive performance was assessed by the area under the receiver operating characteristic curve (AUROC). Results: The AUROCs of using 2nd trimester % time >140 mg/dL (TA140) and week 13-14 TA140 in predicting GDM were 0.81 and 0.74, respectively. The AUROCs for predicting large for gestational age births (LGA) and hypertensive disorders of pregnancy (HDP) using 2nd trimester TA140 were both 0.58. Adding multiple predictors to the models did not meaningfully improve AUROC. When matching the specificity of OGTT, a model using TA140 in weeks 13-14 achieved similar sensitivity to OGTT in predicting HDP (13% vs. 10%, respectively) and LGA (6% for both) (Figure). Conclusion: CGM metrics such as TA140 predicted GDM with high AUROCs as early as 13-14 weeks’ gestation. CGM metrics at 13-14 weeks were statistically similar to OGTT at 24-28 weeks in predicting APOs although sensitivity was low for both. CGM could potentially be used as an alternative to OGTT and/or an early screening tool for elevated hyperglycemia during gestation. Disclosure Z. Li: None. R. Beck: Consultant; Insulet Corporation. Research Support; Insulet Corporation. Consultant; Tandem Diabetes Care, Inc. Research Support; Tandem Diabetes Care, Inc. Consultant; Beta Bionics, Inc. Research Support; Beta Bionics, Inc., Dexcom, Inc., Bigfoot Biomedical, Inc. Consultant; Novo Nordisk. Research Support; Novo Nordisk, Eli Lilly and Company. Consultant; embecta, Vertex Pharmaceuticals Incorporated, Hagar, Ypsomed AG, Sanofi, Zucara Therapeutics, Sequel. C. Durnwald: Consultant; Dexcom, Inc. Research Support; Dexcom, Inc. A.L. Carlson: Research Support; Medtronic, Insulet Corporation, Tandem Diabetes Care, Inc., Eli Lilly and Company, Sanofi. Other Relationship; Novo Nordisk. Advisory Panel; MannKind Corporation. Research Support; Dexcom, Inc. E. Norton: None. R.M. Bergenstal: Other Relationship; Abbott. Research Support; Arkray Marketing. Consultant; Ascensia Diabetes Care, Bigfoot Biomedical, Inc., CeQur. Other Relationship; Dexcom, Inc., Eli Lilly and Company. Consultant; embecta, Hygieia. Research Support; Insulet Corporation. Consultant; MannKind Corporation. Other Relationship; Medtronic, Novo Nordisk. Consultant; Onduo LLC, Roche Diabetes Care. Other Relationship; Sanofi. Research Support; Tandem Diabetes Care, Inc. Other Relationship; UnitedHealth Group. Consultant; Vertex Pharmaceuticals Incorporated, Zealand Pharma A/S. M.L. Johnson: Research Support; Abbott, Lilly Diabetes, National Institute of Diabetes and Digestive and Kidney Diseases, Novo Nordisk, Medtronic, Dexcom, Inc., Leona M. and Harry B. Helmsley Charitable Trust. Consultant; Jaeb Center for Health Research. Research Support; Patient-Centered Outcomes Research Institute, Jaeb Center for Health Research. S.M. Dunnigan: Research Support; Jaeb Center for Health Research, Patient-Centered Outcomes Research Institute, National Institute of Diabetes and Digestive and Kidney Diseases. M. Banfield: None. K.J. Krumwiede: None. J. Sibayan: None. P. Calhoun: None. Funding Study funding was provided by The Leona M. and Harry B. Helmsley and UnitedHealth Group. Dexcom provided the devices used in the study.

Clinical Effectiveness of Continuous Glucose Monitoring in Pregnancies Affected by Type 1 Diabetes

Optimizing Patient Outcomes in Pregnancy: What Continuous Glucose Monitoring Metrics Should We Be Aiming For?

Continuous glucose monitoring-derived glycemic metrics and adverse pregnancy outcomes among women with gestational diabetes: a prospective cohort study

Continuous glucose monitoring metrics and pregnancy outcomes in insulin-treated diabetes: A post-hoc analysis of the GlucoMOMS trial

Continuous glucose monitoring in pregnancies with type 1 diabetes: small increases in time-in-range improve maternal and perinatal outcomes

Continuous Glucose Monitoring for Diabetes Management During Pregnancy: Evidence, Practical Tips, and Common Pitfalls

Continuous Glucose Monitoring-Derived Differences in Pregnancies With and Without Adverse Perinatal Outcomes

Satisfaction with Continuous Glucose Monitoring in Pregnant Patients with Type 1 and Type 2 Diabetes

Practical Considerations for Using Continuous Glucose Monitoring in Patients with Gestational Diabetes Mellitus

Glycemic variability and indices of glycemic control among pregnant women with type 1 diabetes (T1D) based on the use of continuous glucose monitoring share technology

Use of continuous glucose monitoring and hybrid closed‐loop therapy in pregnancy

A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes

Continuous Glucose Monitoring Feedback in the Subsequent Development of Gestational Diabetes: A Pilot, Randomized, Controlled Trial in Pregnant Women

Discrete glucose profiles identified using continuous glucose monitoring data and their association with adverse pregnancy outcomes

Utilizing Continuous Glucose Monitoring for Early Detection of Gestational Diabetes and Pregnancy Outcomes in an Asian Population

Continuous glucose monitoring vs. self-monitoring in pregnant individuals with type 1 diabetes: an economic analysis

Impact of continuous glucose monitoring on hospitalizations and glucose control in people with type 2 diabetes: real‐world analysis

Measuring glucose exposure and variability using continuous glucose monitoring in normal and abnormal glucose metabolism in pregnancy

63-OR: Continuous Glucose Monitoring Prediction of Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes

A Pilot Study Using Continuous Glucose Monitoring among Patients with a Low 1-Hour Glucose Challenge Test Result versus Controls to Detect Maternal Hypoglycemia